Two Sigma Investments, LP Kinnate Biopharma Inc. Transaction History

Two Sigma Investments, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.07 - $2.5 $173,514 - $405,407	162,163 Added 117.96%	299,633 $710,000
Q3 2023 Nov 14, 2023	BUY	$1.38 - $3.31 $33,074 - $79,330	23,967 Added 21.12%	137,470 $192,000
Q2 2023 Aug 14, 2023	BUY	$2.33 - $6.84 $264,461 - $776,360	113,503 New	113,503 $343,000
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $101,143 - $161,666	10,258 New	10,258 $123,000
Q2 2022 Aug 15, 2022	SELL	$7.43 - $13.0 $170,637 - $298,558	-22,966 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$7.73 - $17.99 $177,527 - $413,158	22,966 New	22,966 $259,000
Q4 2021 Feb 14, 2022	SELL	$16.5 - $25.48 $147,312 - $227,485	-8,928 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $159,007 - $222,039	8,928 New	8,928 $206,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.